

Innovative DMPK and Safety Research for Therapeutics and Drug Delivery Systems

Takeda Pharmaceutical are launching an open innovation initiative, inviting researchers to submit their ideas and technologies across five different focus areas, **up to £85k / €100k / \$150k (AUD)**. Summarised below are the interests of Takeda relating to innovative DMPK and safety research for therapeutics and drug delivery systems. In the attached application form, each of these subtopics have been expanded upon to give further detail of proposals that would be within scope. In the attached application form, each of these topics have been expanded upon to give further detail of proposals.



Submissions should be relevant to one or more of the following titles:

- **REF#33: Improvement of omics analysis using artificial intelligence**
- **REF#34: Platform using pattern recognition and machine learning for evaluation of drug response and disease status**
- **REF#35: New drug delivery system and/or human prediction platform for brain targeting of non-small molecule modalities**
- **REF#36: Development of central nervous system-related safety biomarkers using less invasive samples**
- **REF#37: Novel devices, software or methods to evaluate pathological conditions or drug toxicities in animals**

Jurisdictions of Interest

Only submissions from **Europe** and **Australia** will be eligible for this campaign.

Submission Information

To view more details on each area of interest seeking proposals for funding, **download an application form here**. To submit your proposal, please visit **discover.in-part.com**, register, and submit as a Research Project under the appropriate Discover campaign.

Opportunities sought

- 📄 Research projects

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **29th July 2021 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk



Takeda is a global pharmaceutical company focused on solving unmet needs in the areas of oncology, gastroenterology, neuroscience and rare diseases. They have an extensive history of successful collaborations with universities and academic institutions worldwide.